BCRX (STOCKS)
BioCryst Pharmaceuticals Inc
$6.840000
+0.290000 (+4.43%)
Prev close: $6.550000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Charles K. Gayer
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,741.79M
- Employees
- 580
- P/E (TTM)
- -144.61
- P/B (TTM)
- -3.71
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.06 | $0.04 | +0.0241 | +67.13% |
|
Jun 2025 (Q2)
|
$0.04 | $0.01 | +0.0257 | +179.72% |
|
Mar 2025 (Q1)
|
$0.00 | $-0.07 | +0.0695 | +100.00% |
|
Dec 2024 (Q4)
|
$-0.13 | $-0.06 | -0.0719 | -123.75% |
Financial Statements
| Revenues | $599.82M |
| Benefits Costs and Expenses | $606.43M |
| Cost Of Revenue | $15.65M |
| Costs And Expenses | $523.72M |
| Gross Profit | $584.17M |
| Nonoperating Income/Loss | -$82.71M |
| Operating Expenses | $508.07M |
| Selling, General, and Administrative Expenses | $333.16M |
| Research and Development | $174.70M |
| Operating Income/Loss | $76.10M |
| Income/Loss From Continuing Operations After Tax | -$8.78M |
| Income/Loss From Continuing Operations Before Tax | -$6.62M |
| Income Tax Expense/Benefit | $2.16M |
| Net Income/Loss | -$8.78M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$8.78M |
| Net Income/Loss Available To Common Stockholders, Basic | -$8.78M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.05 |
| Diluted Earnings Per Share | -$0.05 |
| Basic Average Shares | 419,609,000 |
| Diluted Average Shares | 437,689,000 |
| Assets | $446.42M |
| Current Assets | $355.68M |
| Inventory | $5.23M |
| Other Current Assets | $350.45M |
| Noncurrent Assets | $90.74M |
| Fixed Assets | $8.40M |
| Other Non-current Assets | $82.34M |
| Liabilities | $834.31M |
| Current Liabilities | $190.24M |
| Accounts Payable | $5.57M |
| Other Current Liabilities | $184.67M |
| Noncurrent Liabilities | $644.08M |
| Equity | -$387.89M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$387.89M |
| Liabilities And Equity | $446.42M |
| Net Cash Flow From Operating Activities | $50.20M |
| Net Cash Flow From Operating Activities, Continuing | $50.20M |
| Net Cash Flow From Investing Activities | $87.59M |
| Net Cash Flow From Investing Activities, Continuing | $87.59M |
| Net Cash Flow From Financing Activities | -$135.99M |
| Net Cash Flow From Financing Activities, Continuing | -$135.99M |
| Exchange Gains/Losses | $38.00K |
| Net Cash Flow | $1.83M |
| Net Cash Flow, Continuing | $1.80M |
| Comprehensive Income/Loss | -$10.66M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$9.93M |
| Other Comprehensive Income/Loss | -$9.93M |